Understanding the Disease
For U.S. Residents Only
Frequently Asked Questions
The following are answers to questions you may have about RYDAPT® (midostaurin) capsules. It is important to also talk with your health care team about questions you may have.
RYDAPT is an oral prescription medicine used to treat adults newly diagnosed with a certain type of acute myeloid leukemia (FLT3+ AML), in combination with certain chemotherapy medicines. Your health care provider will perform a test to make sure RYDAPT is right for you.
RYDAPT is not safe when given to children in combination with chemotherapy. It is not known if RYDAPT is effective in children.
Do not take RYDAPT if you are allergic to midostaurin or any of the ingredients in RYDAPT.
Signs and symptoms of an allergic reaction to RYDAPT have included trouble breathing, flushing, chest pain, throat tightness, and swelling of your lips, mouth, or throat. Get medical help right away if you have any of these signs or symptoms.
- have any lung or breathing problems
- are pregnant or plan to become pregnant. RYDAPT may cause harm to your unborn baby. Tell your health care provider right away if you become pregnant during treatment with RYDAPT or think you may be pregnant
Pregnancy Registry: There is a pregnancy registry that monitors the health of females and their babies exposed to RYDAPT during pregnancy. Females who have taken RYDAPT during pregnancy, or who have been exposed to RYDAPT during pregnancy through a male partner taking RYDAPT, should contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or at https://psi.novartis.com
- If you are able to become pregnant, your health care provider may perform a pregnancy test within 7 days before you start RYDAPT
- Females who are able to become pregnant should use effective birth control (contraception) during treatment with RYDAPT and for at least 4 months after the last dose of RYDAPT
- Males who have female partners who are able to become pregnant should use effective birth control during treatment with RYDAPT and for at least 4 months after the last dose of RYDAPT
- are breastfeeding or plan to breastfeed. It is not known if RYDAPT passes into your breast milk. You should not breastfeed during treatment with RYDAPT and for at least 4 months after the last dose of RYDAPT
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Take RYDAPT exactly as your health care provider tells you.
Your health care provider will tell you how many capsules of RYDAPT you need to take. Do not change your dose unless your health care provider tells you to.
Your health care provider will prescribe medicines to help prevent nausea and vomiting during treatment with RYDAPT.
Take RYDAPT 2 times a day (about every 12 hours apart). Take RYDAPT with food.
Do not open or crush RYDAPT capsules.
If you miss a dose of RYDAPT, take your next dose at your scheduled time. Do not take an extra dose to make up for a missed dose. If you vomit after taking a dose of RYDAPT, do not take an extra dose. Take your next dose at your scheduled time.
RYDAPT may cause serious side effects, including lung problems. RYDAPT may cause lung problems that may lead to death when used alone or in combination with other chemotherapy medicines. Get medical help right away if you have any new or worsening lung symptoms, including cough, chest discomfort, or shortness of breath.
The most common side effects of RYDAPT in people with acute myeloid leukemia (AML) include: low white blood cell counts with fever (febrile neutropenia); nausea; redness, pain, or ulcers on the inside of your mouth (mucositis); vomiting; headache; bruising; muscle or bone pain; nose bleeds; device-related infection; high blood sugar levels (hyperglycemia); and upper respiratory tract infection.
Call or inform your health care provider if nausea, vomiting, or diarrhea occurs, gets worse, or does not go away.
RYDAPT may cause fertility problems in females and males, which may affect your ability to have children. Talk to your health care provider if you have concerns about fertility.
Your health care provider may tell you to decrease your dose, temporarily stop, or completely stop taking RYDAPT if you develop certain side effects during treatment with RYDAPT.
Your health care provider will do blood tests to check you for side effects during treatment with RYDAPT.
These are not all of the possible side effects of RYDAPT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Store RYDAPT at room temperature between 68°F to 77°F (20°C to 25°C). Keep RYDAPT in the original package to protect from moisture.
Keep RYDAPT and all medicines out of the reach of children.
Medicines are sometimes prescribed for conditions not listed in the Patient Information. Do not take RYDAPT for a condition for which it was not prescribed. Do not give RYDAPT to other people, even if they have the same condition or symptoms you have. It may harm them. You can ask your pharmacist or health care provider for information about RYDAPT that is written for health care professionals.
Get more information about FLT3+ AML and treatment with RYDAPT (PDF).